Latest Production Development News

Decidr AI Industries delivered 99% revenue growth and a A$13.6 million annualised exit rate in FY26, but the company’s A$32.4 million loss and auditor-highlighted going concern uncertainty put funding at the centre of its next chapter. Management is targeting A$5 million in annualised savings while seeking to convert early AI deployments into recurring revenue.

Rectifier Technologies has warned of a material uncertainty over its ability to continue as a going concern after revenue fell 41% and its annual loss widened to $6.39 million. An auditor-highlighted liquidity risk now sits alongside a $13 million order book and new EV charging products under development.

Papyrus Australia has produced a second batch of TBS board samples, expanded pulp capacity in Adelaide and secured additional funding as it moves towards commercial supply. The progress comes with testing still incomplete and an estimated 4.87 months of funding available.

AI-Media has set FY27 targets for ARR of $44 million to $46 million and announced an on-market buy-back of up to 20.8 million shares. The combination gives shareholders a clearer scorecard for growth and capital allocation, but neither the guidance nor the full buy-back is guaranteed.

AnteoTech has received $1.905 million from the Australian R&D Tax Incentive, providing fresh cash for its battery materials and life sciences commercialisation efforts. The rebate relates to eligible research conducted during the 2026 financial year.

SportsHero’s FY2026 revenue rose above A$1 million as HeroPlay gained traction through Southeast Asian telco partnerships. But the company remains deeply loss-making, burned A$1.9 million in operating cash and carries a material uncertainty over its ability to continue as a going concern.

EMVision Medical Devices has received a $4.3 million R&D tax refund, adding non-dilutive funding as it progresses clinical work on its emu™ and First Responder devices. The cash arrives against a last reported cash balance of $17.1 million and $4.6 million in remaining grant funding at 30 June 2026.

Nexsen has proposed a 50:50 joint venture with FlashDx Shenzhen to develop and commercialise an enhanced molecular Group B Streptococcus test, using an existing CE-marked platform as its starting point. The proposed venture could shorten Nexsen’s path into hospital and intrapartum testing across Asia-Pacific, but the term sheet remains non-binding and regulatory work is still ahead.

Me Today reported a NZ$2.66 million FY26 profit, but the result was dominated by a NZ$4.12 million gain from losing control of King Honey. The remaining business grew revenue and improved its operating loss, yet continued to consume cash and will rely on October warrant funding.

Stakk says recurring contracts now support 100% of its approximately A$55.2 million FY2027 pro-forma revenue forecast, while fresh international wins are being built into the FY2028 growth story. The company will establish Singapore as its non-US commercial, service and technology hub from November 2026.

News Corp has reported record fiscal 2026 revenue of $9 billion, with Total Segment EBITDA exceeding $1.6 billion and free cash flow reaching $811 million. Dow Jones and digital real estate services led the performance, while the company returned $643 million through share buybacks.

Papyrus Australia moved its banana-fibre technology into early commercialisation during FY26, signing an estimated $4.2 million TBS supply contract and delivering commercial-scale samples. But the company ended the year with $257,077 cash, negative equity and an auditor-flagged material uncertainty over its ability to continue as a going concern.